Compare Elder Pharma with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA SHASUN PHARMA ELDER PHARMA/
SHASUN PHARMA
 
P/E (TTM) x -0.2 123.9 - View Chart
P/BV x 0.1 8.5 1.2% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ELDER PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
SHASUN PHARMA
Mar-14
ELDER PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs38094 403.4%   
Low Rs18846 412.3%   
Sales per share (Unadj.) Rs491.2214.2 229.3%  
Earnings per share (Unadj.) Rs-3.25.3 -59.6%  
Cash flow per share (Unadj.) Rs14.415.8 91.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs376.553.3 705.8%  
Shares outstanding (eoy) m20.5456.62 36.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.60.3 177.2%   
Avg P/E ratio x-89.313.1 -681.4%  
P/CF ratio (eoy) x19.74.4 446.1%  
Price / Book Value ratio x0.81.3 57.6%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m5,8333,958 147.4%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1792,164 100.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,08912,127 83.2%  
Other income Rs m257229 111.9%   
Total revenues Rs m10,34612,356 83.7%   
Gross profit Rs m-7921,009 -78.5%  
Depreciation Rs m361594 60.9%   
Interest Rs m2,756415 664.0%   
Profit before tax Rs m-3,653230 -1,590.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125-73 -172.1%   
Profit after tax Rs m-65302 -21.6%  
Gross profit margin %-7.88.3 -94.3%  
Effective tax rate %-3.4-31.7 10.8%   
Net profit margin %-0.62.5 -26.0%  
BALANCE SHEET DATA
Current assets Rs m9,2406,884 134.2%   
Current liabilities Rs m9,9988,456 118.2%   
Net working cap to sales %-7.5-13.0 57.9%  
Current ratio x0.90.8 113.5%  
Inventory Days Days4662 75.1%  
Debtors Days Days60108 55.7%  
Net fixed assets Rs m10,1244,970 203.7%   
Share capital Rs m206113 181.6%   
"Free" reserves Rs m5,5822,875 194.2%   
Net worth Rs m7,7343,020 256.1%   
Long term debt Rs m4,8891,817 269.0%   
Total assets Rs m22,88213,347 171.4%  
Interest coverage x-0.31.6 -20.9%   
Debt to equity ratio x0.60.6 105.1%  
Sales to assets ratio x0.40.9 48.5%   
Return on assets %11.85.4 218.8%  
Return on equity %-0.810.0 -8.4%  
Return on capital %22.313.3 167.5%  
Exports to sales %3.046.4 6.6%   
Imports to sales %0.414.2 3.0%   
Exports (fob) Rs m3075,622 5.5%   
Imports (cif) Rs m431,728 2.5%   
Fx inflow Rs m3075,843 5.2%   
Fx outflow Rs m1252,173 5.8%   
Net fx Rs m1813,669 4.9%   
CASH FLOW
From Operations Rs m11,754398 2,956.3%  
From Investments Rs m-561-1,635 34.3%  
From Financial Activity Rs m-6,7621,309 -516.7%  
Net Cashflow Rs m4,43271 6,224.3%  

Share Holding

Indian Promoters % 39.6 39.2 101.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 3.6 208.3%  
FIIs % 16.8 17.6 95.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 39.6 91.2%  
Shareholders   16,479 20,750 79.4%  
Pledged promoter(s) holding % 77.6 12.3 631.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  BIOCON   UNICHEM LAB  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 225 Points Higher; Metal and Banking Stocks Witness Buying(Closing)

Extending gains to the fourth consecutive session, Indian share markets witnessed buying interest throughout the day today and ended higher.

Related Views on News

Most Popular

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS